Helsinn Therapeutics (U.S.) Inc., Signs Co-Promotion Agreement for Cancer Therapeutic Zykadia® in the US 5 September 2017
AMAL Therapeutics raises €8 million (CHF 8.8 million) in first closing of Series B financing round 5 September 2017
Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 2 August 2017
HELSINN ADVANCED SYNTHESIS S.A. BIASCA: CONCORSO PER L’ASSEGNAZIONE DI BORSE DI STUDIO 2017/2018 7 July 2017
Helsinn Group Announces Upcoming Presentation of Phase III data in NEPA (netupitant/palonestron) at MASCC/ISOO Congress in Washington DC 20 June 2017
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome 14 June 2017
Linkedin